Ahmed Obeidat, MD, PhD; and Randall Schapiro, MD, FAAN, discuss the prevalence of multiple sclerosis and highlight how the disease has evolved since they began practicing. They also review the impact it has on patients and their support communities.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, comment on early investigations surrounding the impact of multiple sclerosis on cognition and brain health and the current lack of focus regarding its impact on patients.

Experts in neurology comment on the lack of definition of cognitive impairment in multiple sclerosis, highlighting an inability to adequately screen for and measure this disease symptom.

Drs Randall Schapiro and Jeffrey Wilken provide insight into the risk factors and disease progression noted in patients with multiple sclerosis.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, discuss the impact of polypharmacy on cognitive health and share their thoughts on deciding when to cease treatments in patients with multiple sclerosis.

Experts in neurology provide insight into the impact multiple sclerosis can have on patients and hypothesize about initiating treatment before cognitive impairment is observed.

Drs Randall Schapiro and Jeffrey Wilken explore the idea of cognition and brain health biomarkers in multiple sclerosis and provide imaging and diagnostic recommendations.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, share their opinions on the utility of disease-modifying therapies to increase cognition and brain health in patients with multiple sclerosis.

Drs Ahmed Obeidat, Randall Schapiro, and Jeffrey Wilken, provide insight on how to initiate and frame conversations surrounding cognition and brain health with patients with multiple sclerosis.

Randall Schapiro, MD, FAAN, and Jeffrey Wilken, PhD, examine the role that cognition and route of administration play in DMT selection in patients with multiple sclerosis.

Experts in neurology discuss practical considerations for the management of multiple sclerosis, tying in the importance of a collaborative care team and patient involvement.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.